MBRX News and Press, Moleculin Biotech Inc. From 09/05/23

Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire HOUSTON , Sept. 5, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a gr...

2023-08-11 10:08:06 ET Moleculin Biotech, Inc. (MBRX) Q2 2023 Earnings Call Transcript August 11 2023, 08:30 AM ET Company Participants Jenene Thomas - IR Walter Klemp - Chairman & CEO John Paul Waymack - Senior CMO Jonathan Foster - EVP & CFO C...

2023-08-11 06:46:06 ET Moleculin Biotech press release ( NASDAQ: MBRX ): Q2 GAAP EPS of -$0.20 beats by $0.07 . As of June 30, 2023, the Company had cash and cash equivalents of $32.2 million and believes that this cash is sufficient to meet its projected operating req...

Moleculin Reports Second Quarter 2023 Financial Results PR Newswire – Ongoing progress across ongoing clinical development programs with growing body of positive preclinical and clinical data – Released Clinical Trial Update press release yesterday provid...

2023-08-10 10:22:59 ET Major earnings expected before the bell on Friday include: Air Canada ( OTCQX:ACDVF ) Iterum Therapeutics ( ITRM ) Jushi Holdings ( OTCQX:JUSHF ) Moleculin Biotech ( MBRX ) ReWalk Robotics ( RWLK ) For further details se...

2023-08-07 16:00:36 ET Moleculin ( NASDAQ: MBRX ) said that it has retained analytics firm Shareholder Intelligence Services, or ShareIntel, to investigate potential naked short selling of its shares. The company said that information provided by ShareIntel will help it identify...

Moleculin Retains Shareholder Intelligence Services, LLC to Investigate Potential Naked Short Selling PR Newswire HOUSTON , Aug. 7, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceuti...

Moleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and Webcast PR Newswire HOUSTON , Aug. 3, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceu...

Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) PR Newswire Data published in peer-reviewed British Journal of Cancer Research No eviden...

Moleculin to Participate in the Virtual Investor Summer Spotlight Series PR Newswire Live moderated video webcast on Wednesday, July 12 th at 3:00 PM ET HOUSTON , July 6, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ...